Muscle toxicity with statinsy

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 3, 2010, Pages 223-231

  Hedenmalm, Karin ^a,b   Alvan, Gunnar ^c   Öhagen, Patrik ^a   Dahl, Marja Liisa ^b  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug interactions; Hydroxymethylglutaryl CoA Reductase Inhibitors; Rhabdomyolysis

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; HUMAN; KIDNEY DISEASE; MUSCLE CONTRACTION; MUSCLE DISEASE; MUSCLE TOXICITY; MYALGIA; MYOGLOBINURIA; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; ADULT; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG INTERACTION; FEMALE; MALE; MIDDLE AGED; STATISTICAL MODEL; SWEDEN;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; RHABDOMYOLYSIS; RISK FACTORS; SWEDEN;

EID: 77649216010     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1895     Document Type: Article

References (33)

1. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175(9): 486-489.
2. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292(21): 2585-2590.
3. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007; 29(2): 253-260.
4. The SEARCH Collaborative Group. SLCO1B1 variants and statininduced myopathy - a genomwide study. N Engl J Med 2008; 359(8): 789-799.
5. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78(3): 260-277.
6. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80(6): 565-581.
7. Peripheral neuropathy and statins. Prescrire Int 2007; 16(92): 247-248.
8. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006; 27(5): 425-446.
9. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 2004; 19(3): 171-179.
10. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372(6): 432-443.
11. Zhang W, Chen BL, Ozdemir V, et al. SLCO1B1 521T->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 2007; 64(3): 346-352.
12. Tachibana-Iimori R, Tabara Y, Kusuhara H, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19(5): 375-380.
13. Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006; 79(5): 427-439.
14. Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006; 79(5): 419-426.
15. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004; 19(6): 453-455.
16. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73(6): 554-565.
17. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1. Pharmacogenetics 2004; 14(7): 429-440.
18. Takeda M, Noshiro R, Onozato ML, et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMGCoA reductase inhibitors. Eur J Pharmacol 2004; 483(2-3): 133-138.
19. Windass AS, Lowes S,Wang Y, Brown CD. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther 2007; 322(3): 1221-1227.
20. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005; 78(2): 154-167.
21. Lau YY, Huang Y, Frassetto L, Benet LZ. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81(2): 194-204.
22. He YJ, Zhang W, Chen Y, et al. Rifampin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009; 405: 49-52.
23. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35(8): 1400-1407.
24. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 2005; 97: 249-256.
25. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73(6): 538-544.
26. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72(6): 685-691.
27. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311(1): 228-236.
28. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin . J Pharmacol Exp Ther 2003; 304(2): 610-616.
29. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76(2): 167-177.
30. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B. Drug Metab Dispos 2007; 35(5): 779-786.
31. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007; 16(3): 352-358.
32. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36(2): 288-295.
33. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Med (Baltimore) 2005; 84(6): 377-385.